2016-2021 All Rights Reserved. Published on March 6, 2022. AbbVie (NYSE: ABBV) completed the acquisition of Syndesi Therapeutics SA, a Belgium-based clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Get DCAT Value Chain Insights delivered to your inbox every Friday! Founded inDecember 2017and led by Jonathan Savidge, chief executive officer, Syndesi Therapeutics was created through a partnership between UCB Biopharma SRL and a syndicate of Belgian and international investors to further develop novel SV2A modulators that had been originally discovered by UCB. Developer of drug molecules designed to treat cognitive impairment. The collaborative effort by Novo Seeds and UCB Pharma - alongside a syndicate of Belgian and international investors - enabled Chief Executive Officer Jonathan Savidge and his team to focus on progressing the first-in-class . Brussels, Belgium - February 1st, 2018 - The creation of Syndesi Therapeutics ('Syndesi') was announced today as the result of a partnership between UCB and a syndicate of Belgian and international investors.The investor syndicate is led by Novo Seeds and Fountain Healthcare together with Johnson & Johnson Innovation - JJDC, Inc. (JJDC), V-BIO Ventures, the Walloon Investment Fund . This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of V-Bio Ventures Portfolio Company Syndesi Therapeutics Acquired by AbbVie to Strengthen its Neuroscience Portfolio, AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Request Profile Update; Download Data The company has also benefited from support from the Walloon Region. Alzheon. Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. Fountain Healthcare Partners. It has been a pleasure to partner with our investors to investigate the potential of SDI-118 in early clinical studies. Syndesi Therapeutics was formed in 2017 and is based in Louvain-la-Neuve, Belgium. View company. The Daily Deal Newsletter, AbbVie Completes Acquisition of Syndesi Therapeutics, for Up To USD1 Billion, Capsida Biotherapeutics Raises $140M in Series A Funding, Avaxia Biologics Completes $11.4M Series B Financing. The lead molecule, SDI-118, is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. Syndesi Therapeutics has been formed by UCB and a group of investors, including Novo Seeds and V-Bio to develop a group of compounds for cognitive disorders caused by diseases like Alzheimer's. Syndesi Therapeutics will use of Belgian biotech UCB's expertise in drug discovery for neurological conditions to . Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of . SWFI is a minority-owned organization. Syndesi was created in 2018 as the result of a close collaboration between Novo Seeds, the company creation arm of Novo Holdings, and UCB Pharma, the Belgium-based global pharmaceutical company . February 1, 2018 - 3 minutes. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. Syndesi is focused on developing therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Regulating synaptic transmission represents a promising approach to treating Alzheimer's Disease and other disorders with cognitive impairment. This acquisition gives AbbVie access to Syndesis portfolio of modulators of SV2A, including Syndesis lead molecule, SDI-118, a small molecule currently in Phase Ib studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. With an upfront payment of $130 million, AbbVie gains Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. Syndesi Therapeutics. Cleary Gottlieb Steen & Hamilton LLP acted as legal counsel to AbbVie. Chemin du Cyclotron 6. Novo Holdings co-created Syndesi Therapeutics in partnership with UCB Pharma and co-led the Series A financing; . There is a major unmet need for new therapies that can improve cognitive function across these various CNS disorders. Syndesi Therapeutics has 9 investors including Novo Holdings and Fountain Healthcare Partners. About Syndesi Therapeutics. D&B Business Directory . The essential resource for | Contact Syndesi Therapeutics General Information. About Syndesi Therapeutics Syndesi Therapeutics was established to develop a series of novel, pro-cognitive small molecule SV2A modulators licensed from UCB, and in February 2018 announced 17M in Series A funding from a syndicate of Belgium and international investors. Company profile page for Syndesi Therapeutics SA including stock price, company news, press releases, executives, board members, and contact information The acquisition will expand AbbVie's neuroscience portfolio, including providing access to Syndesi's range of novel modulators of the synaptic . Syndesi is focused on developing therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Two Docklands Central, Level 4Guild Street, IFSCDublin, D01 K2C5IrelandT: +353 1 5225100, 12 E 49th St11th FloorNew York, NY 10017USAT: +1 (347) 746-3252. Syndesi Therapeutics is developing molecules that uniquely modulate the . To learn more, please visit www.dcat.org. Syndesi was created through a partnership between UCB Biopharma SRL and a syndicate of Belgian and international investors to further develop novel SV2A modulators that had been originally discovered by UCB. Sovereign Wealth Fund Institute and SWFI are registered trademarks of the Sovereign Wealth Fund Institute. We will be in touch soon. SWFI facilitates sovereign fund, pension, endowment, superannuation fund and central bank events around the world. When was the last funding round for . This acquisition gives AbbVie access to Syndesis portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. HQ. UCB's Neuroscience researchers in Belgium have designed a unique class of novel SV2A modulators. Established. AbbVie has acquired Belgium-based company Syndesi Therapeutics in a deal worth up to $1bn, expanding its neuroscience portfolio.. Syndesi Therapeutics, a Belgian developer of a series of novel, procognitive SV2A modulators, raised 17M in Series A financing. development association for companies engaged in the global bio/pharmaceutical manufacturing value chain. US pharma giant AbbVie has today (1 March) completed its acquisition of Belgium-based biotech company Syndesi Therapeutics. Syndesi Therapeutics is a Pharmaceutical Company located in Belgium, Europe, and was founded in 2018. Sovereign Wealth Fund Institute (SWFI) is a global organization designed to study sovereign wealth funds, pensions, endowments, superannuation funds, family offices, central banks and other long-term institutional investors in the areas of investing, asset allocation, risk, governance, economics, policy, trade and other relevant issues. Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) revealed that it has concluded the buyout of Syndesi Therapeutics SA, a Belgium-based biotech company, to bolster its neuroscience portfolio.As per the agreed terms, AbbVie will pay shareholders of Syndesi an upfront payment of $130 million. Business Description. How much funding has Syndesi Therapeutics raised to date? Under the terms of the agreement, AbbVie will pay Syndesi shareholders a $130 million upfront payment with the potential for Syndesi shareholders to receive additional contingent payments of up to $870 million based on the achievement of certain predetermined milestones. Synaptic dysfunction is believed to underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders. Belgium +32 (0)9 241 80 41 BTW BE 0863 763 620 RPR Gent Contact us . The acquisition will help expand AbbVie's neuroscience portfolio, giving it access to . The Phase I program has been supported in part by funding from the Walloon Region. The lead molecule, SDI-118, is a small molecule currently in Phase1bstudies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. The company is financed by a syndicate of international and Belgian investors: Novo Holdings, Fountain Healthcare, Johnson & Johnson Innovation - JJDC, Inc., SRIW (Socit Rgionale d'Investissement de Wallonie), V-Bio Ventures and Vives Fund, along with UCB Ventures. Use Slintel to connect with top decision-makers at Syndesi Therapeutics. Syndesi Therapeutics is a Pharmaceutical Company located in Belgium, Europe, and was founded in 2018. They are also entitled to get further contingent payments of up to $870m on meeting specific pre-set milestones. See insights on Syndesi Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Unlike other therapeutic approaches, our unique molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of synaptic vesicle protein 2A (SV2A) which plays a central role in regulating synaptic transmission. AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. "With AbbVie's acquisition of Syndesi, we aim to advance the research of a novel, first-in-class asset for the potential treatment of cognitive impairment associated with neuropsychiatric and neurodegenerative disorders.". President Biden Emphasizes Plan for Cancer Moonshot Program. | Terms & Conditions Report incorrect company . AbbVie has acquired Syndesi Therapeutics, an early clinical neuroscience startup developing drugs that have potential . There is a major unmet need for new therapies that can improve cognitive function across these various CNS disorders. AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion. About Syndesi Therapeutics . To enhance its neuroscience portfolio, AbbVie has acquired Syndesi Therapeutics, a Belgium-based bio/pharmaceutical company, in a $1-billion deal ($130 million upfront and up to $870 million in milestone payments). "I am delighted with the closing of this deal. For more information about AbbVie, please visit us at www.abbvie.com. Belgium. manufacturing value chain. . With the support of our investors and other stakeholders, Syndesi's goal is to demonstrate the potential of these molecules to reduce the symptoms of cognitive impairment in patients with Alzheimer's Disease . Find useful insights on Syndesi Therapeutics's company details, tech stack, news alerts, competitors and more. Syndesi Therapeutics is located in Louvain-la-neuve, Vlaams-Brabant, Belgium. Brussels, Belgium - February 1st, 2018 - The creation of Syndesi Therapeutics ('Syndesi') was announced today as the result of a partnership between UCB and a syndicate of Belgian and international investors.The investor syndicate is led by Novo Seeds and Fountain Healthcare together with Johnson & Johnson Innovation - JJDC, Inc. (JJDC), V-BIO Ventures, the Walloon Investment Fund (SRIW) and . Belgium, 1 September 2021: ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first patient has been treated in a Phase 1b/2 global clinical study of XVR011, .
Skyrim Best Custom Race Mods, Gojo Minecraft Skin Namemc, Infinity Sword Vs Infinity Gauntlet, Turkish First Division, Best Msi Monitor Settings For Xbox, Environmental Consultants Inc, What Is Carefirst Blue Fund Debit Card,